Clinical Trial Update: Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients [NA]

View source ↗

Summary

This clinical trial is evaluating whether the SGLT2 inhibitor dapagliflozin can delay the decline of renal function in patients on peritoneal dialysis; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Peritoneal Dialysis

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Sichuan Academy of Medical Sciences | Conditions: Peritoneal Dialysis Complication, Renal Function Aggravated | NA | Status: RECRUITING